Home > Touro College New York > Lander College of Arts and Sciences > The Science Journal of the Lander College of Arts and Sciences > Vol. 5 > No. 2
The Science Journal of the Lander College of Arts and Sciences
Abstract
Chronic myeloid leukemia (CML) is a disorder of blood stem cells in bone marrow, which leads to a rapid production of white blood cells. Of the patients diagnosed with CML, 95% have the Philadelphia (Ph) chromosome, which means that chromosome 22 is smaller than regular (22 q-). Historically, the median survival time for chronic phase CML patients was four to five years, while the accelerated and blast (profusion of immature red blood cells in circulation) phases had a much shorter survival time. Recently, due to the revolutionary new drug imatinib, CML patients diagnosed early have a higher survival rate. Nevertheless, some patients may show resistance to imatinib, and alternative treatments must be considered (Hochhaus and La Rosée 2004).
Recommended Citation
Kops, R. (2012). Imatinib Resistance in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. The Science Journal of the Lander College of Arts and Sciences, 5(2). Retrieved from https://touroscholar.touro.edu/sjlcas/vol5/iss2/6
